摘要
探讨生长抑素治疗肝硬化食管静脉曲张破裂出血的安全性和有效性。对MEDLINE和CNKI中国期刊全文数据库中,2007年4月20日之前已发表的关于生长抑素治疗肝硬化食管静脉曲张破裂出血的随机对照临床试验进行Meta分析。与生长抑素相比,血管加压素副作用发生率高[OR=27.62,95%CI(8.30,91.90)],垂体后叶素止血率低[OR=0.27,95%CI(0.19,0.36)],副作用发生率高[OR=8.87,95%CI(5.74,13.72)],病死率高[OR=5.37,95%CI(2.73,10.57)]。生长抑素是一种安全有效的治疗肝硬化食管静脉曲张破裂出血的药物。
To evaluate the safety and efficacy of somatostatin in the treatment of esophageal variceal bleeding. Correlated Randomized Controlled Clinical Trials （RCT） of somatostatin in the treatment of esophageal variceal bleeding were identified from Medline and National Knowledge Infrastructure （ 1994 - 2007） before 20th, April, 2007. Revman4.2.2 software was used for meta - analysis. Compared with somatc6tatin, vasopressin had higher side effect occurring rate [ OR = 27.62, % 95CI （8.30,91.90） ], hypohpysin had lower bleeding control rate[ OR = 0.27,95 % CI （0.19,0.36） ], higher side effect occurring rate[ OR = 8.87,95 % CI （5.74,13.72） ] and higher mortality rote[ OR = 5.37, 95 % CI （2.73,10.57） ]. Somatc6tatin is safe and effective in treating esophageal variceal bleeding （EVB）.
出处
《医学与哲学（B）》
2007年第11期59-61,共3页
Medicine & Philosophy(B)
